Embolic Agents Segment to Lead Embolotherapy Market During 2022-2028

According to our latest study on "Embolotherapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Disease Indication, Procedure, and End User," the market is expected to grow from US$ 3,341.49 million in 2021 to US$ 5,758.28 million by 2028; it is estimated to grow at a CAGR of 8.1% from 2022 to 2028. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.

Embolotherapy is blocking arteries with an inserted balloon catheter to prevent untreatable bleeding. It is an endovascular treatment aimed at sealing abnormal blood vessels to control bleeding and reduce tumors. Embolotherapy plays a major role in managing pelvic tract bleeding, postpartum adjustment, and the management of cervical pregnancy. This therapy helps treat iatrogenic solid organs, vascular injuries, and the non-surgical treatment of organ trauma, including the liver, spleen, and kidneys.

The five most common types of cancer are breast, prostate, cervical, lung, and colorectal. However, of these five cancers, the leading cause of cancer-related death is lung cancer. According to National Cancer Registry (NCR), in 2020, ~110,000 new cancer cases were diagnosed in South Africa, with more than 56,000 cancer-related deaths, representing a quarter of premature noncommunicable disease-related mortality. The significant cancer burden is projected to increase in the coming decades, with the incidence of new cancer cases projected to rise to 138,000 and 175,000 in 2030 and 2040, respectively. Moreover, according to the American Cancer Society journal, in 2021, an estimated 1.9 million new cancer cases were diagnosed and 608,570 cancer deaths in theUS.

Embolization is used to stop bleeding or block blood flow to a tumor or abnormal tissue area. It is also used to treat liver and kidney cancer and neuroendocrine tumors. Embolizing agents, including embolic microspheres (beads), are used to restrict the vascular supply of tumors and can be loaded with chemotherapeutic medicines, which elute and diffuse into the tissue. The vascular embolization device controls hemorrhage due to aneurysms, certain types of tumors, and arteriovenous malformations. It helps prevent aneurysms and tumors from growing and causing harm to essential organs. Thus, the rising prevalence of cancer cases is creating a high demand for embolotherapy products.

Based on product, the embolotherapy market is segmented into embolic agents and support devices. The embolic agents segment held a larger market share in 2021, and the same segment is anticipated to register a higher CAGR in the market during the forecast period. Embolic agents apply mechanical occlusion to block blood flow in one or more blood vessels or abnormal vascular areas. Embolic agents come in a variety of forms, each with its own set of properties and applications. Various embolic agents are placed by using certain ways, such as via catheters into the blood vessels, to inhibit blood flow to a specified area. Embolizing agents like embolic microspheres (beads) restrict the vascular supply of tumors and can be loaded with chemotherapeutic medicines, which elute and diffuse into the tissue. The increasing use of embolic agents in various interventional radiology procedures and advancements in such agents, such as calibrated microspheres for bland embolization and drug-eluting microspheres, are the reasons for the growth of the segment.

Impact of COVID-19 Pandemic on Embolotherapy Market

The COVID-19 pandemic impacted the growth of the embolotherapy market negatively. During the lockdown periods, the healthcare industry encountered unprecedented challenges. Manufacturing units were closed, affecting the production of medical devices and other equipment. Moreover, the supply chains of medical products were disrupted, resulting in an increase in warehouse inventory of manufactured products. As most surgery departments were closed and the focus was shifted entirely to COVID care, it resulted in a drastic decrease in the number of embolotherapy procedures. In this scenario, Brazil has encountered enormous difficulties in managing cancers such as head and neck surgeries, chronic neurological disorders like brain aneurysms, and from headache to neurodegenerative diseases. Similarly, in Australia, the COVID-19 pandemic resulted in a reduction in cardiac surgery. The study reported in Heart, Lung & Circulation showed that from March to June 2020, 136 adults underwent cardiac surgery, representing a 21% drop in operative caseload in Australia. As a result, there was reduced use of products associated with embolotherapy, which negatively impacted the growth of the embolotherapy market.

Abbott Laboratories, Boston Scientific Corporation, Cook Medical LLC, Johnson & Johnson Consumer Inc., Medtronic, Acandis GmbH, Terumo Corporation, Balt USA LLC, Stryker Corporation, and Guerbet LLC are among the key players operating in the embolotherapy market.

The report segments the embolotherapy market as follows:

The embolotherapy market is segmented based on product, disease indication, procedure, end user, and geography. Based on product, the market is segmented into embolic agents and support devices. Based on disease indication, the market is segmented into cancer, peripheral vascular disease, neurological disease, urological and nephrological disorder, gastrointestinal disorder, and other. Based on procedure, the market is segmented into transcatheter arterial embolization (TAE), transcatheter arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), and transarterial chemoembolization (TACE). On the basis of end user, the market is segmented into hospital & clinic, ambulatory surgical center, and other end user.

Geographically, the embolotherapy market has been segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the rest of Europe), APAC (China, India, Japan, Australia, South Korea, and the rest of Asia Pacific), the MEA (Saudi Arabia, the UAE, South Africa, and the Rest of the MEA), and SAM (Brazil, Argentina, and the Rest of SAM).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com